Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

https://investors.apogeetherapeutics.com/news-releases/news-release-details/apogee-therapeutics-announces-13-billion-strategic-financing?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz--AE_lRviz5uTdzuaSeIS7j4n4Tii-OET1hZ-xR5Y7-Wtpsqj7yRT7EJFT9KJgYg7PS590IQ8XYea9EzAsP5JTzyL8UQQ&_hsmi=420814327&utm_content=420814327&utm_source=hs_email Blackstone Life Sciences, a private equity fund, is providing Apogee Therapeutics with up to $1.3 billion to pay for the Phase 3 development and potential commercialization of zumilokibart, the biotech's long-acting treatment for atopic dermatitis.